Acquisitions21 Dec 2024, 09:00 pm
Suven Pharmaceuticals Acquires 56% Stake in NJ Bio for USD 64.4 Million
AI Summary
Suven Pharmaceuticals Ltd has completed the acquisition of 56% equity share capital of NJ Bio, Inc. The acquisition was made at an aggregate consideration of USD 64.4 million, which includes USD 15 million of primary equity infusion into NJ Bio. The acquisition was disclosed on December 7, 2024, and completed on December 20, 2024, in compliance with Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023.
Key Highlights
- Suven Pharmaceuticals acquires 56% equity share capital of NJ Bio, Inc.
- The acquisition consideration is USD 64.4 million, including USD 15 million primary equity infusion.
- The acquisition was disclosed on December 7, 2024, and completed on December 20, 2024.
- The acquisition is in compliance with Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023.